| ASCELIA PHARMA AB |
| Schweden |
| Gesundheit |
| SE0010573113 / A2H81X |
| 7ZA (Frankfurt) |
| FRA:7ZA, ETR:7ZA, 7ZA:GR |
| - |
| https://www.ascelia.com/ |
|
Ascelia Pharma AB (publ) is a biotech company specializing in the development and commercialization of novel drugs for orphan oncology treatments. The company focuses on addressing unmet medical needs in rare cancer conditions through two key drug ca..
>Volltext.. |
| 32.68 Mio. EUR |
| 28.19 Mio. EUR |
| - |
| - |
| -7.15 Mio. EUR |
| -0.06 EUR |
| 0.09 Mio. EUR |
| 4.67 Mio. EUR |
| -6.77 Mio. EUR |
| 4.02 |
| - |
| 4.72% |
| - |
| - |
| - |
| - |
| ASCELIA |
| 05.04.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|